A Phase II, Open Label Pilot Study to Evaluate the Safety and Efficacy of A Bioresorbable Subcutaneous Implant of CUV1647 in Patients With Solar Urticaria (SU)
Latest Information Update: 17 Apr 2014
At a glance
- Drugs Afamelanotide (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Sponsors Clinuvel Pharmaceuticals
- 17 Apr 2014 New trial record